ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
Dow Jones
44.424,25
-0,32%
Euro vs US Dollar
1,05025
0,00%
Bitcoin
105.062,93
0,32%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Precision BioSciences Inc (DTIL)

  7. Precision BioSciences Inc (DTIL) News

DTIL

Precision BioSciences (DTIL)

Precision BioSciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DTIL
DatumZeitQuelleÜberschriftSymbolFirma
24/01/202521h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202503h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202503h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202503h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202503h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
22/01/202521h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
22/01/202521h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
21/01/202522h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
09/01/202516h01Business WirePrecision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
09/01/202514h00Business WireiECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
08/01/202514h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
02/01/202513h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
31/12/202413h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
31/12/202413h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
30/12/202412h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
18/12/202413h01Business WirePrecision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
21/11/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
21/11/202413h01Business WirePrecision BioSciences to Participate in Upcoming November Investor ConferencesNASDAQ:DTILPrecision BioSciences Inc
15/11/202413h00Business WirePrecision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
06/11/202401h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
06/11/202401h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
06/11/202401h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
04/11/202421h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
04/11/202421h49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
04/11/202413h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DTILPrecision BioSciences Inc
04/11/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
04/11/202413h01Business WirePrecision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
29/10/202412h01Business WirePrecision BioSciences to Report Third Quarter Results on November 4, 2024NASDAQ:DTILPrecision BioSciences Inc
28/10/202412h01Business WirePrecision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024NASDAQ:DTILPrecision BioSciences Inc
24/10/202422h15Business WirePrecision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual CongressNASDAQ:DTILPrecision BioSciences Inc
 Showing the most relevant articles for your search:NASDAQ:DTIL

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
TG
MBG
MercedesBenz
TG
432
Arbor Metals
CCOM
SILVER
SILVER
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
NASDAQ
NVDA
NVIDIA
COIN
XRPUSD
Ripple
TG
DTE
Deutsche Telekom
USOTC
RHHBY
Roche (QX)
CCOM
US500
US 500
NYSE
XOM
Exxon Mobil
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten